Profile avatar
alcmi.bsky.social
The Addario Lung Cancer Medical Institute (ALCMI) is a non-profit international consortium comprised of over 25 of the world's premier oncology research institutions. We fund and support investigator-led lung cancer clinical trials.
149 posts 121 followers 238 following
Prolific Poster
Posts 50 Comments 0

At the upcoming 26th Annual International Lung Cancer Congress, researchers are preparing to discuss what happens next when resistance emerges in EGFR-mutated NSCLC. #lungcancer www.targetedonc.com/view/experts...

submitted 6 hours ago • 0 comments

For those tracking innovation in lung cancer treatment, this recap from Calley Jones, Ph.D., for the American Association for Cancer Research blog is worth your time. #lungcancer www.aacr.org/blog/2025/05...

submitted 1 day ago • 0 comments

An exploratory subgroup analysis of the EMPOWER-Lung 1 trial, published in Cancer, reveals some promising findings for first-line cemiplimab (Libtayo) in patients with advanced NSCLC, brain metastases, and high PD-L1 expression. #lungcancer www.onclive.com/view/cemipli...

submitted 2 days ago • 0 comments

PLK4 inhibition is emerging as a compelling strategy to enhance the impact of radiation in non–small cell lung cancer. #lungcancer aacrjournals.org/mct/article-...

submitted 3 days ago • 0 comments

The FDA just granted accelerated approval to AbbVie's Emrelis (telisotuzumab vedotin), a first-in-class treatment for a specific subset of non-small cell lung cancer patients. #lungcancer www.medpagetoday.com/hematologyon...

submitted 4 days ago • 0 comments

Don’t miss this 🎧: Our board & medical committee member Marc Muskavitch, PhD joins UpStage Lung Cancer’s podcast for a powerful convo on ALK+ #lungcancer. Why early detection & #BiomarkerTesting are critical to improving outcomes. #lcsm 🦻upstagelungcancer.org/podcasts/livin…

submitted 6 days ago • 0 comments

If you’re interested in where #lungcancer vaccines are at relative to #melanoma, check out this @togaanz.bsky.social podcast with @gvlongphdmd.bsky.social and Ken OByrne. podcasts.apple.com/au/podcast/v... open.spotify.com/episode/0OJb...

submitted 5 days ago • 0 comments

Biomark Diagnostics Inc. just reached a major milestone, validating the high accuracy of its liquid biopsy test for early-stage lung cancer detection. #lungcancer www.biospace.com/press-releas...

submitted 5 days ago • 0 comments

At #ELCC2025, final survival results from the phase III MARIPOSA trial showed that patients with EGFR-mutated non–small cell lung cancer lived significantly longer when treated with amivantamab-vmjw plus lazertinib compared to osimertinib. #lungcancer ascopost.com/issues/may-1...

submitted 6 days ago • 0 comments

Proud to share a new article from ALCMI's COO and Executive Director, Richard Erwin, shedding light on the urgent need for innovation, collaboration, and bold action in the fight against small cell lung cancer. #lungcancer alcmi.org/media-resour...

submitted 7 days ago • 0 comments

For patients with advanced non-small cell lung cancer who haven’t responded to immune checkpoint inhibitors, CAN-2409 plus valacyclovir is showing remarkable promise. #lungcancer www.healio.com/news/hematol...

submitted 8 days ago • 0 comments

iOctura recently launched a randomized Phase I/II study investigating whether roginolisib, combined with dostarlimab, can help reprogram the immune system to prevent or reverse resistance in non-small cell lung cancer. #lungcancer www.prnewswire.com/news-release...

submitted 9 days ago • 0 comments

A new study from the Fred Hutchinson Cancer Research Center, published in Science Advances, takes a look at why small cell lung cancer can respond so dramatically to chemotherapy, only to relapse just as quickly. #lungcancer www.fredhutch.org/en/news/cent...

submitted 10 days ago • 0 comments

At ALCMI's consortium member, Montefiore Einstein Comprehensive Cancer Center, Dr. Nitin Ohri and his team are advancing NSCLC treatment options with the phase 2 SPRINT trial. #lungcancer www.onclive.com/view/persona...

submitted 11 days ago • 0 comments

Suppressing APOBEC enzymes—key drivers of tumor mutations—could dramatically delay drug resistance in non-small cell #lungcancer (#NSCLC), up to 1200%! Targeting the generation of variation may be the best route to personalized and durable treatments 🧪. ysph.yale.edu/news-article... #Medsky

submitted 13 days ago • 1 comment

In a recent interview with OncLive, Dr. Alexis Chidi of Memorial Sloan Kettering Cancer Center explained how the gold standard of lung cancer surgery—removing an entire lobe of the lung (a lobectomy)—is giving way to less invasive options. #lungcancer www.onclive.com/view/less-is...

submitted 12 days ago • 0 comments

Wow, new research presented at hashtag#ESTRO2025 introduces the RAPID-RT study from The Christie NHS Foundation Trust, a significant advancement in lung cancer radiotherapy evaluation. #lungcancer www.news-medical.net/news/2025050...

submitted 13 days ago • 0 comments

New research led by Dr. Teja Voruganti and published in the American Society of Clinical Oncology (ASCO) Educational Book dives deep into perioperative lung cancer therapy strategies—what’s working, what’s promising, and what’s still unclear. #lungcancer ascopubs.org/doi/10.1200/...

submitted 14 days ago • 0 comments

A new study from Yale School of Public Health, led by Dr. Jeffrey Townsend, offers an interesting strategy to slow cancer down by targeting the very process that helps it outsmart our best therapies. #lungcancer medicalxpress.com/news/2025-05...

submitted 15 days ago • 0 comments

A new study published in Nature Magazine's Experimental & Molecular Medicine explores how cannabidiol (CBD)—better known for managing epilepsy—can dramatically enhance the cancer-fighting potential of etoposide in non-small cell lung cancer. #lungcancer www.nature.com/articles/s12...

submitted 16 days ago • 0 comments

Phase 2 KEYLYNK-007 trial findings suggest a new avenue through the combination of olaparib and pembrolizumab in previously treated solid tumors harboring homologous recombination repair mutations and/or homologous recombination deficiency. #lungcancer www.oncologynewscentral.com/oncology/tum...

submitted 17 days ago • 0 comments

Dr. Yuanyuan Zhang and researchers at UT Southwestern Medical Center have found that devimistat—an FDA-designated orphan drug—may supercharge the impact of radiation therapy. #lungcancer www.utsouthwestern.edu/newsroom/art...

submitted 18 days ago • 0 comments

Fascinating and concerning study out of Memorial Sloan Kettering Cancer Center. Dr. Jung Hun Oh and colleagues discovered that lung cancer can hijack genes normally crucial for fetal development and immune evasion during pregnancy. #lungcancer www.mskcc.org/news/pregnan...

submitted 19 days ago • 0 comments

If we want to beat lung cancer, we need better models. Mouse models have been essential for research, but they’re fragmented, and silos make it hard to compare results across studies. #lungcancer aacrjournals.org/cancerres/ar...

submitted 20 days ago • 0 comments

This week, The New England Journal of Medicine published a new study on Boehringer Ingelheim's zongertinib that could be a game changer. #lungcancer www.nejm.org/doi/full/10....

submitted 21 days ago • 0 comments

For years, the KRAS gene mutation in cancer was considered "undruggable," impacting so many, particularly in lung, pancreatic, and colorectal cancers. Then came the first breakthrough for one subtype. #lungcancer www.mskcc.org/news/potenti...

submitted 22 days ago • 0 comments

At the American Association for Cancer Research Annual Meeting, researchers shared early but exciting news about zoldonrasib, an experimental drug targeting the KRAS G12D mutation in non-small cell lung cancer. #lungcancer www.moffitt.org/endeavor/arc...

submitted 23 days ago • 0 comments

Congratulations to Raymond Chalmé, Dr. Joan Schiller, and AstraZeneca! Each will be honored at the Lung Cancer Research Foundation's 2025 Evening of Innovation gala. #lungcancer www.prnewswire.com/news-release...

submitted 24 days ago • 0 comments

The EU has approved Tumor Treating Fields (TTFields) combined with immunotherapy or docetaxel in metastatic NSCLC after progression. The phase 3 LUNAR trial demonstrated a significant overall survival benefit. #lungcancer www.cancernetwork.com/view/ttfield...

submitted 25 days ago • 0 comments

Wow, "remarkable change" doesn't even begin to cover it when we're talking about the evolution of care for EGFR-mutated non-small cell lung cancer. Dr. Shirish Gadgeel and Dr. Robert Figlin discuss. #lungcancer www.oncologynewscentral.com/podcast/how-...

submitted 26 days ago • 0 comments

Phase 3 data published in The Lancet Respiratory Medicine show that high-dose, twice-daily thoracic radiotherapy paired with concurrent chemotherapy holds that promise for patients battling limited-stage SCLC. #lungcancer www.cancernetwork.com/view/high-do...

submitted 27 days ago • 0 comments

A new study in AACR Journals' Clinical Cancer Research by Dana-Farber Cancer Institute's Dr. Federica Pecci and colleagues looks at immune checkpoint inhibitors and what happens when these therapies are cut short due to immune-related adverse events. #lungcancer aacrjournals.org/clincancerre...

submitted 28 days ago • 0 comments

Researchers at Stanford University School of Medicine have developed RARE-seq, an ultrasensitive method for detecting cell-free RNA (cfRNA) in blood plasma, and the implications for cancer detection and monitoring are enormous. #lungcancer www.nature.com/articles/s41...

submitted 29 days ago • 0 comments

Only 18% of eligible patients in the U.S. get screened for lung cancer. Our consortium member, City of Hope, explored the reasons in a recent article. #lungcancer www.cityofhope.org/hope-matters...

submitted 30 days ago • 0 comments

Amgen's Phase III DeLLphi-304 trial found that Imdelltra (tarlatamab-dlle) delivered a statistically significant improvement in overall survival for patients with SCLC that had progressed following platinum-based chemotherapy. #lungcancer www.pharmexec.com/view/amgen-i...

submitted 31 days ago • 0 comments

The treatment landscape for EGFR-positive non-small cell lung cancer (NSCLC) is changing, and pharmacists are becoming key decision-makers in navigating that complexity. #lungcancer www.pharmacytimes.com/view/more-op...

submitted 32 days ago • 0 comments

We’ve made incredible progress in biomarker testing for lung cancer, but are we moving fast enough to save lives? #lungcancer www.oncologynurseadvisor.com/news/biomark...

submitted 33 days ago • 0 comments

Congratulations to Yvonne Diaz and Korina Pateli-Bell for receiving awards from Lung Cancer Europe for their impactful advocacy! #lungcancer oncodaily.com/blog/lung-ca...

submitted 34 days ago • 0 comments

Amgen just announced that IMDELLTRA (tarlatamab-dlle) significantly improved overall survival compared to standard chemo in patients whose cancer had already progressed after platinum-based treatment. #lungcancer www.amgen.com/newsroom/pre...

submitted 35 days ago • 0 comments

New research in Nature Magazine's Scientific Reports found a synergy between soy saponins and isoflavones. The duo significantly reduced NNK-induced lung cancer in a cigarette carcinogen-induced model. #lungcancer www.nature.com/articles/s41...

submitted 36 days ago • 0 comments

Researchers at Roswell Park Comprehensive Cancer Center, led by Dr. Sayan Chakraborty, have uncovered agrin’s role in driving treatment resistance and relapse in lung adenocarcinoma. #lungcancer

submitted 37 days ago • 0 comments

The FDA just gave the green light to a second Phase 1a/b IND for ST-001, SciTech’s investigational fenretinide nanoparticle therapy—this time for patients with SCLC. #lungcancer firstwordpharma.com/story/5948449

submitted 38 days ago • 0 comments

In his powerful editorial for JCO Oncology Practice, Dr. Gregory Videtic revisits the decades-old clinical standard of twice-daily thoracic radiotherapy. #lungcancer

submitted 39 days ago • 0 comments

New research in Annals of Oncology shows that a breath-based diagnostic tool—an “electronic nose”—is getting surprisingly close to clinical reality. #lungcancer

submitted 40 days ago • 0 comments

At ALCMI, we specialize in remote, decentralized trials. Our COO and Executive Director, Richard Erwin, wrote an article about remote DCT trials and how they are advancing lung cancer science. Check it out! #lungcancer

submitted 41 days ago • 0 comments

What happens when lung cancer strikes those who've never smoked? Dr. Bryant Lin, co-founder of Stanford CARE and a stage IV never-smoker lung cancer patient himself, encapsulated the urgency of this issue at the inaugural Stanford Lung Cancer Summit. #lungcancer

submitted 42 days ago • 0 comments

What if we could detect a lung cancer patient’s relapse months before it’s visible on scans? A recent study in Nature Magazine sheds light on the powerful potential of molecular residual disease (MRD) analysis. #lungcancer

submitted 43 days ago • 0 comments

Congratulations to our consortium member, Baptist Health! The organization is utilizing Intuitive Surgical Devices' Ion robotic-assisted bronchoscopy system to improve early detection and treat hard-to-reach lung nodules.

submitted 44 days ago • 0 comments

The European Lung Cancer Congress 2025 highlighted game-changing innovations in lung cancer care, including clinical trials like MARIPOSA and APOLLO 11, advancements in precision medicine, and the emerging role of AI in immunotherapy.

submitted 45 days ago • 0 comments

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on a perioperative regimen involving Bristol Myers Squibb’s Opdivo (nivolumab) for patients with resectable non-small cell lung cancer. #lungcancer

submitted 46 days ago • 0 comments